Monocyte‐To‐Lymphocyte Ratio as a Predictor of Thrombosis Progression in Patients With Polycythemia Vera: A Retrospective Study
Authors:
- 10 November 2025
- journal article
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 48 (2) , 305-315
Abstract
Introduction: Thrombosis is a leading cause of mortality in polycythemia vera (PV), yet little is known about early predictors of thrombosis progression. Emerging evidence links systemic inflammation to thrombosis risk. This study assessed hematological inflammatory parameters, including the neutrophil‐to‐lymphocyte ratio (NLR), monocyte‐to‐lymphocyte ratio (MLR), platelet‐to‐lymphocyte ratio (PLR), systemic immune‐inflammation index (SII), systemic inflammatory response index (SIRI), and aggregate index of systemic inflammation (AISI), for their utility in predicting thrombosis progression in PV. Methods: This retrospective study analyzed 102 PV patients (2008–2024) and 115 healthy controls. Clinical and laboratory data, including thrombotic events, were examined. Patients were stratified into low‐and high‐risk groups, further categorized by thrombosis progression. Inflammatory biomarkers were derived from baseline blood counts. Results: Median follow‐up was 51 months, the 10‐year thrombotic events‐free survival rate was 84.30%, and 21 patients (20.59%) showed thrombosis progression. PV patients had higher NLR, MLR, PLR, SII, SIRI, and AISI than controls. NLR, MLR, SIRI, and AISI were associated with an increased risk of thrombosis compared to the low‐risk group. In the progression group, high monocytes, NLR, MLR, SIRI, AISI, and previous thrombosis were notably correlated. ROC analysis showed that MLR (AUC = 0.739), SIRI (AUC = 0.714), AISI (AUC = 0.670), and NLR (AUC = 0.649) had the highest predictive ability for thrombosis progression. Multivariate analysis identified MLR (HR = 6.979) and previous thrombosis (HR = 4.494) as independent risk factors. Conclusion: These findings support recent reports linking systemic inflammation to thrombosis risk in PV patients and highlight for the first time that MLR may serve as a valuable prognostic biomarker for thrombotic events.Keywords
This publication has 34 references indexed in Scilit:
- Circadian rhythms and cancer: implications for timing in therapyDiscover Oncology, 2024
- The impact of wet cupping on haematological and inflammatory parameters in a sample of Jordanian team playersHeliyon, 2024
- Activated PRKCD-mediated neutrophil extracellular traps pathway may be the prothrombotic mechanism of neutrophils in polycythemia vera patients based on clinical retrospective analysis and bioinformatics studyInternational Immunopharmacology, 2023
- Association of inflammation and abnormal lipid metabolism with risk of thrombosis and thrombosis progression in patients with polycythemia vera: a retrospective studyAnnals of Hematology, 2023
- Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2023
- Prediction of thrombosis in polycythemia vera: Development and validation of a multiple factor-based prognostic score systemResearch and Practice in Thrombosis and Haemostasis, 2023
- The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasmsAmerican Journal of Hematology, 2022
- High platelet-to-lymphocyte ratio predicts poor survival of elderly patients with hip fractureInternational Orthopaedics, 2020
- Thromboembolic events in polycythemia veraAnnals of Hematology, 2019
- Mechanisms of thrombogenesis in polycythemia veraBlood Reviews, 2015